Form 10-Q Valeant Pharmaceuticals For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall St set for mixed open ahead of SK Hynix listing; Middle East in focus
- Oil heads for weekly gains as Middle East supply risks persist
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
Valeant Pharma (VRX) Files Presentation on Philidor; Says No Evidence of Illegal Activity To-Date
October 26, 2015 7:28 AM EDTValeant Pharma (NYSE: VRX) filed a presentation related to its conference call on Philidor today. The presentation is embedded below and the following are some highlights from the document:
Says it has no right to remove CEO and management of... MoreValeant Pharma (VRX) Says Philidor Accounting is Appropriate
October 26, 2015 6:16 AM EDTValeant Pharma (NYSE: VRX) announced that its Audit and Risk Committee and the full Board of Directors have reviewed the company's accounting for its Philidor arrangement and have confirmed the appropriateness of the company's related revenue recognition and accounting treatment.
Based on its review conducted to date, Valeant also believes that the company is in compliance with applicable law. In light of the recent allegations made regarding Philidor, however, the Board of Directors has decided to establish an ad hoc committee of the board to review allegations related to the company's business relationship... More
Valeant Pharma (VRX) Adds ValueAct's Morfit as Director
October 26, 2015 6:13 AM EDTValeant Pharma (NYSE: VRX) announced the addition of G. Mason Morfit, President of ValueAct Capital, to its board of directors effective immediately. Morfit had originally served on the Valeant Board of Directors from May 2007 to May 2014.
"I am pleased to welcome... More
